Magnesium Citrate

• Osmotic laxative for occasional constipation
• Colonoscopy and pre-procedure bowel preparation
• Correcting measured magnesium deficiency
• General magnesium supplementation at lower doses
• Sleep and muscle relaxation (weaker, mixed evidence)

Magnesium citrate is a magnesium salt of citric acid, chemically, the salt of magnesium cation (Mg2+) with the tribasic anion of citric acid, typically formulated as the trimagnesium dicitrate or similar stoichiometry. Elemental magnesium content is approximately 11-16% by weight depending on the specific salt form (the commonly distributed trimagnesium dicitrate provides ~16% elemental Mg). The magnesium-citrate bond is moderate chelation (weaker than glycinate amino acid chelation but substantially stronger than ionic carbonate or oxide salts), providing reasonable bioavailability through intestinal absorption pathways that include both passive paracellular transport and active TRPM6/TRPM7-mediated transport. Once dissociated in the gut and absorbed, the magnesium ion enters the same physiological pool as magnesium from any other source, there is no "citrate-specific" magnesium pharmacology in tissues. The form differentiation is therefore primarily about: (1) intestinal absorption efficiency and osmotic effects; (2) citrate-specific secondary effects independent of magnesium; (3) practical product characteristics (palatability, dose-form, cost). Magnesium itself performs the same essential biology described comprehensively in the mag-glycinate deep entry, cofactor for >300 enzymatic reactions including ATP utilization, oxidative phosphorylation, protein synthesis, DNA stability, neurotransmitter signaling, and muscle contraction; structural component of bone (~50-60% of body magnesium concentrated in skeleton); essential for vitamin D activation; antagonist of calcium at NMDA receptors and L-type calcium channels; modulator of GABAergic and serotonergic signaling. The clinical applications for magnesium status correction (constipation, muscle cramps, premenstrual syndrome, hypertension adjunct, migraine prevention, type 2 diabetes glycemic adjunct, cardiac arrhythmia management) apply across forms; the form selection optimizes for the specific clinical application context. The citrate-specific characteristics matter substantially for clinical positioning. First, the osmotic laxative effect: magnesium citrate produces stronger osmotic laxation than mag-glycinate at equivalent elemental magnesium dose, citrate ions remain in the intestinal lumen longer than glycine (which is rapidly absorbed and metabolized), producing sustained osmotic gradient that draws water into the gut and promotes peristalsis. This makes magnesium citrate the preferred form for users with constipation, the dominant form for clinical bowel preparation (Citroma, Magnesium Citrate USP Solution for pre-colonoscopy bowel cleansing), and less preferred than glycinate for users with normal bowel function seeking magnesium repletion without laxative effect. Second, citrate-specific kidney stone prevention: citrate inhibits calcium oxalate and calcium phosphate kidney stone crystallization through direct binding of urinary calcium and through urinary alkalinization (citrate is metabolized to bicarbonate in the liver, producing urinary alkalinization that increases citrate solubility). Potassium citrate (Urocit-K) is established pharmaceutical therapy for hypocitraturic calcium nephrolithiasis; magnesium citrate provides similar though somewhat less potent urinary citrate elevation. Third, sustained-release characteristics: the citrate counter-ion provides moderate buffering that may smooth absorption kinetics versus more rapidly dissociating forms (oxide, sulfate). Fourth, palatability and dose-form: magnesium citrate is widely available as palatable powder formulations (Natural Vitality Calm being the dominant consumer brand) that dissolve readily in water with mild citrus flavor, enabling higher-dose supplementation than capsule forms. Fifth, cost: magnesium citrate is substantially less expensive than chelated amino acid forms (glycinate, malate, threonate), making it the dominant form in mass-market supplementation and combination products.

Standard magnesium citrate supplementation aims at 200-400mg elemental magnesium daily for general repletion and clinical applications. Adult RDA for total magnesium is 320mg/day women, 420mg/day men; most adults can achieve dietary RDA through whole foods (leafy greens, nuts, seeds, whole grains, dark chocolate, legumes). Supplemental magnesium citrate is appropriate for users with documented inadequate intake, specific clinical applications, or constipation contexts. The Upper Limit (UL) for supplemental magnesium (excluding dietary) is 350mg/day for non-pharmaceutical context, the limit reflects GI tolerance threshold (laxative effects, diarrhea) at higher chronic doses. Acute pharmaceutical magnesium citrate use (Citroma laxative, pre-colonoscopy preparation) substantially exceeds this limit for specific short-term clinical purpose. Take with or without food, absorption is acceptable either way; food administration may modestly reduce GI effects. The form selection from the magnesium category matters substantially: mag-citrate is preferred for constipation contexts, kidney stone prevention (citrate-specific), and cost-effective general supplementation; mag-glycinate preferred for sleep/anxiety applications and users with sensitive bowels; mag-malate sometimes preferred for energy metabolism applications. The Natural Vitality Calm powder format (325mg elemental Mg per 2 teaspoon serving) provides the dominant US consumer experience, palatable, dissolves in water, mild citrus flavor, easy dose titration. The capsule format (NOW Foods, Solgar, Pure Encapsulations, others) provides 100-200mg elemental Mg per capsule for users preferring solid dose forms. Distribute total dose across 2-3 servings rather than single large dose if exceeding 400mg total daily, reduces GI effects and improves compliance. The kidney stone prevention application warrants specialist urology/nephrology coordination with urinary chemistry monitoring (Litholink and similar) to guide individual dosing. The pre-colonoscopy bowel preparation use case follows specific gastroenterology protocol (typically 150-300mL of Citroma USP solution) substantially distinct from general supplementation. The drug interaction profile is similar to other magnesium forms, quinolone antibiotics, tetracyclines, levothyroxine, and bisphosphonates require timing separation (take magnesium 2-4 hours apart from these medications); proton pump inhibitor chronic use may produce hypomagnesemia warranting supplementation. The pregnancy and lactation contexts: AI is elevated (350-400mg/day pregnancy depending on age; 310-360mg/day lactation); modest citrate supplementation is generally well-tolerated and may help pregnancy constipation. Pediatric dosing follows age-specific AIs with specialist coordination for therapeutic supplementation contexts.

Adult RDA women

320mg/day

Adult RDA men

420mg/day

Pregnancy RDA

350-400mg/day (age-dependent)

Lactation RDA

310-360mg/day

Upper Limit (UL) supplemental

350mg/day

Standard supplementation

200-400mg elemental Mg/day

Constipation/bowel motility

400-1000mg/day; titrate to effect

Kidney stone prevention

400-600mg/day; specialist coordination

• Magnesium Citrate Powder (Natural Vitality Calm)

  Rating: gold

  The dominant US consumer magnesium citrate brand, palatable powder formulation that dissolves in water with mild citrus flavor. Natural Vitality (acquired by The Clorox Company) provides 325mg elemental magnesium per 2 teaspoon serving as magnesium carbonate-citrate dissolved in water (the carbonate-citrate conversion happens with water dissolution producing the active magnesium citrate complex). Substantial consumer brand heritage; effective supplementation form for higher-dose magnesium repletion.

• Magnesium Citrate Capsules (NOW Foods, Solgar, Pure Encapsulations)

  Rating: gold

  Standard magnesium citrate capsule formulations from major reputable manufacturers. Typical content 100-200mg elemental Mg per capsule. Reasonable cost positioning; standard form for general supplementation when avoiding powder format. Convenient dose flexibility.

• Magnesium Citrate USP Solution (Citroma, Generic)

  Rating: gold

  FDA-recognized OTC saline laxative, pharmaceutical-grade magnesium citrate liquid concentrate providing approximately 1.745g elemental magnesium per 10oz bottle. Used for acute constipation relief and pre-colonoscopy bowel preparation. Specific pharmaceutical use case distinct from general supplementation. Mainstream pharmacy availability without prescription.

• Magnesium Citrate Liquid Concentrate (Trace Minerals, Eidon)

  Rating: good

  Liquid concentrate formulations for users preferring liquid supplementation or precise dose titration. Various manufacturers (Trace Minerals Research, Eidon Mineral Supplements). Premium pricing relative to powder or capsule forms.

• Magnesium Citrate-Malate Combinations

  Rating: gold

  Combination magnesium citrate + magnesium malate formulations providing both citrate and malate counter-ions. Mechanistically reasonable for users seeking comprehensive magnesium support with both citrate (kidney stone prevention, osmotic effects) and malate (preliminary evidence for energy metabolism, fibromyalgia). Available from Designs for Health, Thorne, and similar premium brands.

• Magnesium Citrate + Glycinate Combinations

  Rating: gold

  Combination formulations providing both citrate (sustained release, modest osmotic effect, kidney stone prevention) and glycinate (smooth absorption, minimal GI effects, sleep/anxiety applications). Available from various premium manufacturers. Mechanistically reasonable for users seeking comprehensive coverage.

• Magnesium Citrate in Sleep/Stress Formulations

  Rating: good

  Magnesium citrate commonly included in sleep and stress combination formulations (Calm Sleep, Mag07 combinations, various others), typically combined with melatonin, L-theanine, ashwagandha, or other sleep/stress supplements. Reasonable comprehensive supplementation; verify magnesium dose specifically. Note that magnesium glycinate is generally preferred over citrate for sleep applications due to reduced laxative effects.

• Magnesium Citrate-Containing Multivitamins

  Rating: good

  Many multivitamins include magnesium citrate as their magnesium source given cost-effectiveness and reasonable bioavailability. Typical content 50-100mg elemental Mg as part of broader formulation. Reasonable foundational supplementation; verify dose adequacy for specific clinical applications.

• Chronic constipation (functional bowel)

  Strength of evidence for this group: strong

  The osmotic laxative effect of magnesium citrate makes it preferred form for users with chronic constipation. Effective dose 400-1000mg elemental Mg/day producing meaningful stool softening and bowel motility support. FDA-recognized OTC laxative status (Citroma). Reasonable component of comprehensive constipation management; coordinate with gastroenterology for refractory constipation or warning symptoms.

• Calcium oxalate kidney stone prevention

  Strength of evidence for this group: modest

  Citrate-specific kidney stone prevention through urinary citrate elevation and alkalinization. Magnesium citrate provides combined Mg and citrate effects supporting calcium oxalate stone prevention. Specialist urology/nephrology coordination; urinary chemistry monitoring guides individual dosing. Potassium citrate (Urocit-K) is more potent pharmaceutical alternative for established stone disease.

• Mild magnesium deficiency / repletion

  Strength of evidence for this group: modest

  Magnesium citrate provides reasonable bioavailability for mild magnesium repletion. Most adults achieve adequate magnesium through diet (leafy greens, nuts, seeds, whole grains, dark chocolate); targeted supplementation reasonable for users with documented deficiency or low dietary intake. Mag-glycinate typically preferred over citrate for users with normal bowel function seeking repletion without laxative effect.

• Pre-colonoscopy bowel preparation

  Strength of evidence for this group: strong

  Pharmaceutical use of magnesium citrate USP solution for pre-colonoscopy bowel cleansing. Specific clinical use case under gastroenterology coordination. Effective osmotic preparation; standard component of pre-procedural bowel prep protocols.

• Pregnancy constipation

  Strength of evidence for this group: modest

  Pregnancy commonly produces constipation through progesterone-mediated GI motility reduction. Magnesium citrate at modest doses (200-400mg elemental Mg/day) is reasonable for pregnancy constipation. Coordinate with OB-GYN; preferred over harsher laxative agents during pregnancy.

• Premenstrual syndrome (PMS) symptoms

  Strength of evidence for this group: modest

  Magnesium supplementation supported by modest evidence for PMS symptom reduction. Either citrate or glycinate forms appropriate; citrate may produce additional GI motility support beneficial for some users.

• Cardiac arrhythmia adjunctive

  Strength of evidence for this group: cautious

  IV magnesium has established cardiology use in torsades de pointes and select arrhythmias. Oral magnesium supplementation provides modest support; either citrate or glycinate appropriate at moderate doses. Specialist cardiology coordination essential.

• Type 2 diabetes (glycemic adjunct)

  Strength of evidence for this group: modest

  Modest evidence for magnesium supplementation improving HbA1c and insulin sensitivity in type 2 diabetes. Either citrate or glycinate appropriate; effect sizes modest. Reasonable adjunct to standard diabetes management.

• Hypertension adjunctive

  Strength of evidence for this group: modest

  Modest BP-lowering effects with magnesium supplementation in mildly hypertensive users. Either citrate or glycinate appropriate. Reasonable adjunct to standard hypertension management.

• Migraine prevention

  Strength of evidence for this group: modest

  Magnesium supplementation supported by modest evidence for migraine prevention (typical doses 400-600mg elemental Mg/day). Either citrate or glycinate appropriate; some users prefer citrate format for compliance.

• Healthy adults seeking sleep/anxiety support

  Strength of evidence for this group: cautious

  Magnesium supports GABA function and sleep architecture; mag-glycinate is typically preferred over citrate for sleep/anxiety applications due to reduced GI laxative effects. Citrate at modest doses may be appropriate; users with sensitive bowels should consider glycinate form instead.

• Renal insufficiency / CKD

  Strength of evidence for this group: avoid

  Impaired renal magnesium excretion in CKD creates hypermagnesemia risk with magnesium supplementation. Coordinate with nephrology; standard magnesium supplementation typically avoided in moderate-to-severe CKD without specialist monitoring.

• Healthy adults (general supplementation)

  Strength of evidence for this group: modest

  Adult RDA 320-420mg/day (women/men); most adults can achieve dietary adequacy. Modest supplementation (200-400mg elemental Mg/day) reasonable for users with low dietary intake or specific clinical applications. Citrate is cost-effective and bioavailable; glycinate preferred for users with sensitive bowels.

• Vitamin D3

  Interaction: synergy

  Mechanistically integrated, magnesium is cofactor for vitamin D activation (25-hydroxylase, 1-alpha-hydroxylase), and VDR signaling supports magnesium absorption. Common combination in comprehensive bone nutrition formulations.

• Calcium

  Interaction: synergy

  Integrated bone nutrition framework, calcium provides bone mineral substrate; magnesium provides activation cofactor and bone matrix structural role. Common combination in bone supplementation. Mechanistically inseparable in bone biology.

• Vitamin K2

  Interaction: synergy

  Magnesium is cofactor for vitamin K-dependent carboxylation reactions activating osteocalcin and MGP. Common combination in comprehensive bone nutrition.

• Vitamin B6

  Interaction: synergy

  Magnesium-B6 combination supported by historical and modern evidence for premenstrual syndrome, anxiety, and mood applications. Common combination in PMS and stress formulations.

• Potassium Citrate

  Interaction: synergy

  For kidney stone prevention, combination citrate sources (magnesium citrate + potassium citrate, the pharmaceutical Urocit-K or similar) provide additive urinary citrate elevation. Specialist urology/nephrology coordination.

• Quinolone Antibiotics (Ciprofloxacin, Levofloxacin)

  Interaction: caution

  Magnesium chelates fluoroquinolones reducing absorption substantially. Separate by 2-4 hours; coordinate with prescribing physician.

• Tetracycline Antibiotics

  Interaction: caution

  Magnesium chelates tetracyclines reducing absorption. Separate by 2-3 hours.

• Levothyroxine

  Interaction: caution

  Magnesium can substantially reduce levothyroxine absorption. Take levothyroxine first thing in morning on empty stomach; magnesium with meals or evening. Coordinate with endocrinology.

• Bisphosphonates (Alendronate, Risedronate)

  Interaction: caution

  Magnesium reduces bisphosphonate absorption. Take bisphosphonate first thing in morning on empty stomach; magnesium supplementation separated by hours. Standard osteoporosis management timing.

• Iron Supplements

  Interaction: caution

  Magnesium can modestly inhibit iron absorption when co-administered. Separate iron supplementation by 2 hours if iron deficiency is clinical concern.

• Proton Pump Inhibitors (Omeprazole, Pantoprazole)

  Interaction: synergy

  Chronic PPI use (>1 year) can produce hypomagnesemia; magnesium supplementation may be specifically warranted in chronic PPI users. FDA has issued safety communications about chronic PPI hypomagnesemia risk.

• Diuretics (Loop and Thiazide)

  Interaction: synergy

  Loop diuretics (furosemide) and thiazide diuretics produce magnesium wasting; supplementation may be specifically warranted. Coordinate with prescribing physician; periodic serum magnesium monitoring reasonable.

• Renal Insufficiency

  Interaction: avoid

  Impaired renal magnesium excretion in CKD creates hypermagnesemia risk. Standard supplementation avoided in moderate-severe CKD without specialist coordination.

• Other Magnesium Forms

  Interaction: caution

  Combining citrate with glycinate or other magnesium forms is reasonable for diverse benefit profile but watch total elemental magnesium dose to stay within reasonable supplementation range.

Look for: specific elemental magnesium content per serving disclosed clearly; appropriate dose for intended use (200-400mg elemental Mg for general supplementation, 400-1000mg for constipation); USP or NSF third-party verification; reputable manufacturer with quality control disclosure; heavy metal testing disclosure. Avoid: products with only compound weight disclosed (without elemental magnesium); aggressive marketing claims about citrate-specific benefits beyond evidence base; very high single-dose products without specific clinical context; combination products that obscure individual magnesium dose; products from manufacturers without third-party testing. The Natural Vitality Calm category specifically: reasonable product with substantial consumer heritage; not pharmacologically superior to generic magnesium citrate but provides excellent palatability and dose flexibility through powder format.

Magnesium citrate has a substantial dual history, pharmaceutical OTC laxative (Citroma and equivalents, established 19th-20th century) and modern consumer dietary supplement (substantially expanded through the 1980s-2020s). The pharmaceutical history begins with characterization of magnesium salts as saline laxatives in 19th century pharmacology; Epsom salt (magnesium sulfate), milk of magnesia (magnesium hydroxide), and magnesium citrate USP solution all established as standard OTC laxative options. The FDA OTC monograph review process formalized these as recognized laxatives; Citroma and equivalent generic magnesium citrate USP solutions remain widely available pharmacy products. Pre-colonoscopy bowel preparation use became established through the 1970s-1980s as colonoscopy became standard colorectal cancer screening, magnesium citrate, polyethylene glycol, and sodium phosphate solutions all standard bowel prep options. The modern dietary supplement era for magnesium citrate developed substantially through the 1980s-1990s. The Walker 2003 Magnesium Research bioavailability comparison and subsequent research established magnesium citrate as substantially superior to magnesium oxide for absorption, driving consumer supplement industry shift away from oxide toward citrate and other better-bioavailable forms. The Kappeler 2017 modern comparative work continued this evidence base. The Natural Vitality Calm category cultural emergence developed substantially through the 1990s-2010s. Peter Gillham's Natural Vitality company developed the Calm powder formulation in the 1990s; the brand grew substantially through the 2000s through health food retail and direct-to-consumer marketing. The "Anti-Stress Drink" positioning emphasized the stress-magnesium connection and the palatable powder format. The Clorox Company acquired Natural Vitality in 2018, expanding distribution into mass-market retail. The cultural positioning of magnesium citrate powder as wellness supplement category has substantially shaped Western consumer magnesium supplementation patterns. The kidney stone prevention pharmacology developed substantially through Charles Pak's work at UT Southwestern (1985 J Urol foundational citrate alkalinization characterization) and subsequent urology and nephrology integration. Potassium citrate (Urocit-K) emerged as primary pharmaceutical citrate for established stone disease; magnesium citrate provides complementary supplementation for users seeking both Mg and citrate benefits. The Litholink urinary monitoring system (since 1990s) and similar laboratory services support specialist-coordinated citrate supplementation for stone prevention. The form-differentiation era in magnesium supplementation developed substantially through the 2010s-2020s as consumer awareness of bioavailability differences increased. The mag-glycinate vs mag-citrate vs mag-malate vs mag-threonate vs mag-taurate (and other forms) category proliferation reflects sophisticated consumer interest in form-specific applications. Modern guidance positions citrate as cost-effective bioavailable foundation with osmotic and citrate-specific applications; glycinate as preferred form for users with sensitive bowels or sleep applications; malate for energy metabolism; threonate for CNS applications; etc. The Mathers 2019 Magnesium Research comparative work and subsequent research has provided more rigorous form-comparison evidence supporting differential clinical application guidance. The mainstream nutritional medicine integration of magnesium supplementation across applications (constipation, kidney stones, migraines, hypertension, diabetes, PMS, cardiovascular, sleep) has matured substantially through this period.

1. 19th centuryMagnesium salts characterized as saline laxatives
2. Early-mid 20th centuryCitroma and similar OTC magnesium citrate USP solutions established
3. 1970s-1980sPre-colonoscopy bowel preparation standardization
4. 1985Pak citrate kidney stone prevention pharmacology (J Urol)
5. 1990sNatural Vitality Calm category development; Litholink urinary monitoring
6. 1990Lindberg magnesium citrate bioavailability (J Am Coll Nutr)
7. 2003Walker comparative bioavailability (Magnes Res)
8. 2017Kappeler modern comparative bioavailability (Eur J Nutr)
9. 2018The Clorox Company acquires Natural Vitality
10. 2019Mathers magnesium citrate vs glycinate comparison (Magnes Res)
11. 2010s-2020sForm-differentiation era; sophisticated consumer category proliferation

• Whether magnesium citrate provides clinically meaningful advantages over magnesium glycinate for users with normal bowel function, the primary differentiator (osmotic laxative effect) is undesirable for many supplementation contexts.
• Whether the kidney stone prevention application of magnesium citrate is comparable to potassium citrate (Urocit-K pharmaceutical alternative), magnesium provides additional mineral support but citrate alkalinization may be less potent.
• Whether the Natural Vitality Calm category cultural positioning (stress/anxiety/sleep marketing) is adequately supported by mechanism, citrate is generally less preferred than glycinate for these applications.
• Whether differential pharmacokinetic profiles (citrate faster Tmax, stronger osmotic effects; glycinate smoother absorption, less GI effects) translate to clinically meaningful differences in chronic supplementation contexts.
• Whether magnesium citrate has specific advantages in cardiovascular health applications beyond general magnesium effects.
• Whether the form selection (citrate vs glycinate vs malate vs threonate vs other) should be more rigorously guided by individual user characteristics (bowel function, sleep quality, kidney stone risk, cost tolerance).
• Whether population-level magnesium deficiency is more prevalent than current dietary surveys suggest, some research has suggested substantial inadequacy across modern Western populations.
• How the pre-colonoscopy bowel preparation use case affects population magnesium citrate awareness and supplementation patterns.

Universally available globally as dietary supplement and FDA-recognized OTC laxative. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Pharmaceutical preparations: Citroma (Magnesium Citrate USP Solution) is the foundational FDA-recognized OTC saline laxative; multiple generic equivalents available; pre-colonoscopy preparation protocols use higher-dose citrate formulations. Major retail supplement brands include Natural Vitality Calm (The Clorox Company, dominant US powder brand), NOW Foods, Solgar, Pure Encapsulations, Thorne, Designs for Health, Doctor's Best, Life Extension, and most multivitamin manufacturers. Mass-market drugstore brands (Nature Made, Sundown Naturals, Vitafusion) commonly use magnesium citrate as their magnesium source given cost-effectiveness. Combination products include Calm Sleep (Natural Vitality + melatonin), Mag07 (Aerobic Life, magnesium-oxygen claim formulation), and many sleep/stress combinations. The Natural Vitality Calm category cultural emergence through the 2000s-2020s has substantially shaped consumer magnesium supplementation patterns, the brand has become essentially synonymous with magnesium citrate powder supplementation in the US market. Production is widely distributed, magnesium citrate is produced through industrial chemistry combining magnesium carbonate or oxide with citric acid (substantial commodity supply). Quality variation across consumer supplements is modest given the well-established chemistry; reputable manufacturers with quality verification provide consistent products. Third-party testing (USP, NSF) provides standard quality assurance. The category has substantial price variation reflecting brand positioning rather than fundamental raw material costs, powder formulations typically cost more per elemental magnesium than capsule forms; premium brands cost more than mass-market equivalents at similar elemental content.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Form

Magnesium citrate (Mg2+ salt of citric acid)

Elemental magnesium content

~11-16% (depending on stoichiometry)

Adult RDA total magnesium

320mg women / 420mg men daily

Pregnancy RDA

350-400mg/day (age-dependent)

Lactation RDA

310-360mg/day

Upper Limit (UL) supplemental

350mg/day

What follows is unfinished work on our side, not a finding about Magnesium Citrate. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.